论文部分内容阅读
目的:观察平消胶囊对手术后Ⅰ~Ⅱa期非小细胞肺癌的1、3年生存率,免疫功能及生存质量的影响。方法:全部患者均经病理证实的非小细胞肺癌。根据临床和术后病理确定为Ⅰ~Ⅱa期,Karnofsky评分≥70分,年龄在35~75岁。治疗组术后两周给予平消胶囊治疗,一次4~5粒,3次/d,90d为一疗程,对照组术后不给予任何治疗。治疗结束后对两组病人的1、3年生存率,免疫功能及生存质量进行评估。结果:治疗组1、3年生存率分别为95.5%、66.5%;对照组为94.0%、64.5%。两组1、3年生存率差异无显著性(P>0.05),治疗组外周血T细胞亚群、T淋巴细胞的比值明显高于对照组(P<0.05)。生存质量(生活质量调查、体重、卡氏评分)明显高于对照组(P<0.05)。结论:平消胶囊具有增加患者免疫力及提高生存质量的作用,但对术后Ⅰ~Ⅱa期非小细胞肺癌的生存率(1、3年生存率)无明显影响。
Objective: To observe the effect of Pingxiao capsule on the one and three year survival rate, immune function and quality of life of stage Ⅰ ~ Ⅱa non-small cell lung cancer after operation. Methods: All patients were pathologically confirmed non-small cell lung cancer. According to clinical and postoperative pathology identified as Ⅰ ~ Ⅱ a period, Karnofsky score ≥ 70 points, aged 35 to 75 years. The treatment group was given Pingxiao capsule two weeks after operation, once for 4 ~ 5 capsules, 3 times / d, 90d for a course of treatment, the control group did not give any postoperative treatment. After the treatment, the 1, 3-year survival rate, immune function and quality of life of the two groups of patients were evaluated. Results: The 1-year and 3-year survival rates were 95.5% and 66.5% in the treatment group and 94.0% and 64.5% in the control group, respectively. There was no significant difference in the 1,3-year survival rates between the two groups (P> 0.05). The ratio of T lymphocyte subsets and T lymphocytes in the peripheral blood of the treatment group was significantly higher than that of the control group (P <0.05). Quality of life (quality of life survey, weight, Karnofsky score) was significantly higher than that of the control group (P <0.05). Conclusion: Pingxiao capsule has the effect of increasing patient immunity and improving quality of life, but has no significant effect on the survival rate of patients with stage Ⅰ ~ Ⅱa non - small cell lung cancer (1, 3 year survival rate).